Results 41 to 50 of about 464,133 (328)
Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. [PDF]
PLoS ONE, 2013 Multiple myeloma (MM), the second most common hematopoietic malignancy, remains an incurable plasma cell (PC) neoplasm. While the proteasome inhibitor, bortezomib (Bz) has increased patient survival, resistance represents a major treatment obstacle as ...
Holly A F Stessman +5 more
doaj +1 more source
Experimental and Molecular Medicine, 2021 Breast cancer (BC) is the most prevalent malignant neoplasm among women and is the fifth most common cause of cancer-associated death worldwide. Acquired chemoresistance driven by genetic and epigenetic alterations is a significant clinical challenge in ...
Xiaoping Pan +4 more
semanticscholar +1 more source
Cancer Biology & Medicine, 2012 Objective To explore the interaction of Anxa2 with P-Glycoprotein (P-gp) in the migration and invasion of the multidrug-resistant (MDR) human breast cancer cell line MCF-7/ADR.Methods A pair of short hairpin RNA (shRNA) targeting P-gp was transfected ...
Hai-chang Zhang +6 more
doaj +1 more source
Current Medical Science, 2021 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy characterized by recurrent skin nodules, an aggressive clinical course with rapid involvement of hematological organs, and a poor prognosis with poor overall survival.
Wei-Tzu Cheng +4 more
semanticscholar +1 more source
Asian Journal of Medical Sciences, 2014 Chronic myeloid leukemia (CML) is a haematopoietic neoplasm with clinically distinct phases and BCR⁄ABL1 oncogene. Imatinib mesylate, a potent inhibitor of BCR-ABL was highly effective in CML but later in-vitro derived cell line with resistance namely ...
Rajat Rana
doaj +1 more source
Understanding the role of phenotypic switching in cancer drug resistance [PDF]
Journal of Theoretical Biology, 490 (2020), 110162, 2020 The emergence of acquired drug resistance in cancer represents a major barrier to treatment success. While research has traditionally focused on genetic sources of resistance, recent findings suggest that cancer cells can acquire transient resistant phenotypes via epigenetic modifications and other non-genetic mechanisms.
arxiv +1 more source
Loss of KDM6A confers drug resistance in acute myeloid leukemia
Leukemia, 2018 Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm resulting from the malignant transformation of myeloid progenitors. Despite intensive chemotherapy leading to initial treatment responses, relapse caused by intrinsic or acquired drug ...
Sophie M. Stief +23 more
semanticscholar +1 more source
Frontiers in Cell and Developmental Biology, 2021 Hepatocellular carcinoma (HCC) is an aggressive, chemo resistant neoplasm with poor prognosis and limited treatment options. Exploring activated pathways upon drug treatment can be used to discover more effective anticancer agents to overcome therapy ...
Mustafa Karabicici +5 more
semanticscholar +1 more source
Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates [PDF]
BioImpacts, 2019 Despite rapid advances in diagnostic and treatment approaches, the overall survival rate of cancer has not been improved. Colorectal cancer (CRC) is recognized as the third leading cause of neoplasm-related deaths worldwide, in large part due to its ...
Mostafa Akbarzadeh Khiavi +2 more
doaj +1 more source
Mutational pathway determines whether drug gradients accelerate evolution of drug-resistant cells [PDF]
Phys. Rev. Lett. 109, 088101 (2012), 2012 Drug gradients are believed to play an important role in the evolution of bacteria resistant to antibiotics and tumors resistant to anti-cancer drugs. We use a statistical physics model to study the evolution of a population of malignant cells exposed to drug gradients, where drug resistance emerges via a mutational pathway involving multiple mutations.
arxiv +1 more source